Wegovy weight loss in Letchworth: the facts behind the headlines

The myth doing the rounds: 'Wegovy just suppresses your appetite for a bit'

The biggest misconception about Wegovy is that it is a short-term appetite suppressant, roughly equivalent to eating less willpower. It is not. Semaglutide is a GLP-1 receptor agonist, it binds to receptors that regulate hunger, fullness and glucose handling in ways that extend well beyond a temporary 'full feeling'. Gastric emptying slows, the brain receives different satiety signals, and the cumulative effect over months is a sustained reduction in caloric intake that most people find genuinely difficult to achieve through diet alone. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average weight loss of around 15% over 68 weeks in adults without type 2 diabetes, not a cosmetic trim, but a clinically meaningful change in body weight. Understanding that mechanism matters because it also explains the side-effect profile, the titration schedule, and why stopping abruptly tends to reverse the benefit. This is a medicine that works with your physiology over time, not one that overrides it briefly. Anyone telling you otherwise is oversimplifying.

That distinction also shapes who is genuinely suited to it, and if you are wondering whether Wegovy is worth it given everything the treatment involves, that question is worth thinking through carefully before your first consultation. The evidence behind semaglutide for weight management is worth reading if you want the full picture before your first consultation.

What the NHS route actually looks like from Letchworth, and what it does not cover

NHS access to Wegovy is governed by NICE guidance (TA875), which recommends it only within a specialist weight management service, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity. Ethnic-background thresholds are typically 2.5 kg/m² lower. NHS England's phased rollout of tirzepatide (a different medicine) through GP practices began in 2025, but Wegovy on the NHS remains routed through specialist services with significant waiting times in most areas, including Hertfordshire. NICE's appraisal of semaglutide for weight management (TA875) sets out the full eligibility criteria. For people in Letchworth who do not meet the NHS thresholds, or who do not want to join a waiting list, a regulated private pharmacy is the legal alternative, provided a proper clinical assessment takes place first. That assessment is not optional; it is required by law for any prescription-only medicine.

If you are weighing up whether the treatment is worth pursuing at all, this honest look at whether Wegovy is worth it addresses that question directly.

Cost, access, and what a legitimate private prescription actually involves

Private Wegovy pricing in the UK has moved significantly since Eli Lilly's list-price increase in September 2025 shifted market expectations. Reported private prices for semaglutide typically range from around £149 to £375 per month depending on dose and provider, though those figures vary. Before comparing numbers, it is worth understanding what a headline price should include: the clinical consultation, the prescription, any dose-review support, aftercare access, and delivery. A price that excludes some of those elements is not necessarily cheaper, it is incomplete. A breakdown of Wegovy pricing in the UK covers what to look for when evaluating any provider's costs.

At nume, one transparent price covers consultation, prescription, clinical re-review before every repeat, and free next-working-day tracked delivery. There are no subscriptions and no auto-renewals. Every consultation is personally read by a GPhC-registered Independent Prescriber, a real clinician, the same day. When your order is approved and dispatched, DPD sends a tracking link; the package itself arrives in plain, unbranded packaging with no indication of its contents. How the service works explains each step. We are not the cheapest option available. That is a deliberate choice, for a prescription medicine, the right question is not which provider charges the least, but whether the supply chain, clinical oversight and aftercare are genuinely sound. Our GPhC pharmacy registration (9012878) is publicly verifiable on the regulator's own register.

Side effects and safety: what to watch for, and when to act

Wegovy's side-effect profile is dominated by gastrointestinal effects, nausea, loose stools, constipation, reflux and fatigue are most commonly reported, particularly in the early weeks of treatment or after a dose increase. These tend to settle as the body adjusts, though they do not disappear for everyone. The titration schedule (starting at 0.25mg and increasing roughly every four weeks, guided by your prescriber) exists largely to reduce their severity. The NHS semaglutide medicines page lists the full known side-effect profile, including less common but more serious effects to be aware of.

Two signals that always warrant prompt medical attention: severe or persistent stomach pain that radiates to the back (a potential sign of pancreatitis, highlighted in an MHRA Drug Safety Update in January 2026), and symptoms of gallbladder problems. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing) require emergency help. If something feels wrong between consultations, reaching our aftercare team is straightforward; nume prescribers are available seven days a week. Side effects and missed doses are always discussed with your prescriber or by consulting the Patient Information Leaflet supplied with your medicine, not estimated from general guidance. For a broader overview of the treatment and what to expect week to week, our Wegovy treatment page covers the practical detail.